Back to search results

Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals

IsraelRecruitingPHASE4

Conditions

HIV Infected Individuals · Osteopenia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Rambam Medical Center, Haifa, Israel

    Contact: Study coordinator (Eynat Kedem, Doctor) · e_kedem@rambam.health.gov.il · 972536283187
    Contact: Principal Investigator (Eynat Kedem, Doctor)

  • Hadassah Hebrew University Medical Center, Jerusalem, Israel

    Contact: Study coordinator (Hila Elinav, Doctor) · hilaelinav@gmail.com · +972587874340
    Contact: Study coordinator (Daniella Iluz) · danielaI@hadassah.org.il · 972504048807
    Contact: Principal Investigator (Hila Elinav, Doctor)
    Auryan Szalat, Doctor (Sub-investigator)
    Shalev Lussheimer, Doctor (Sub-investigator)
    Keren Olshtain-pops, Doctor (Sub-investigator)
    Sarah Israel, Doctor (Sub-investigator)
    'Yonatan Oster, Doctor (Sub-investigator)
    Maya Korem, Doctor (Sub-investigator)
    Daniel Grupel, Doctor (Sub-investigator)
    Efrat Orenbuch-Harroch, Doctor (Sub-investigator)

  • Sheba Medical Center, Ramat Gan, Israel

    Contact: Study coordinator (Itzchak Levy, Preoffesor) · itsik.levi@sheba.health.gov.il · 972526667525
    Itzchak Levy, Proffesor (Sub-investigator)
Study leads

  • Hila Elinav, Doctor

    Principal Investigator

    Hadassah University Medical center

  • Eynat Kedem, Doctor

    Principal Investigator

    Rambam Health Care Campus

  • Itzchak Levy, Proffesor

    Principal Investigator

    Sheba Medical Center

View source on ClinicalTrials.gov(opens in a new tab)